SCHEMBL1574579

SCHEMBL1574579

O=C(Nc1ccc2ccccc2c1)N1CC(N2CCC(c3ccccc3)CC2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.55
▸ RAB9A P51151 6/20 0.55
▸ MAPT P10636 5/20 0.55
▸ TP53 P04637 5/20 0.55
▸ SMN1; SMN2 Q16637 5/20 0.55
▸ NFKB1 P19838 2/20 0.55
▸ NFKB2 Q00653 2/20 0.55
▸ RELA Q04206 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ HTT P42858 1/20 0.55
▸ KDM4E B2RXH2 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ CCR5 P51681 1/20 0.49
▸ STAT1 P42224 1/20 0.49
▸ MCHR1 Q99705 1/20 0.48
▸ GRIN2B Q13224 5/20 0.48
▸ PTPN7 P35236 1/20 0.47
▸ DUSP3 P51452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574804 0.87 NPC1 (0.71) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1575306 0.86 KDM4E (0.54) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL1575394 0.85 MAPT (0.76) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1575113 0.84 CYP3A4 (0.53) NPC1RAB9ATP53SMN1; SMN2KDM4E
SCHEMBL1574686 0.84 CYP3A4 (0.53) NPC1RAB9ATP53SMN1; SMN2KDM4E
SCHEMBL1575392 0.84 GRIN2B (0.67) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1575495 0.84 TP53 (0.67) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1575686 0.84 NPC1 (0.74) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1574652 0.84 GRIN2B (0.57) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1574855 0.84 CCR3 (0.61) SMN1; SMN2GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 — — EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 — — US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 — — US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB NPC1 413/4885RAB9A 898/4885MAPT 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback